Terms: = Breast cancer AND IL2, IL-2, 3558, ENSG00000109471, P60568 AND Prognosis
36 results:
1. PTPRC promoted CD8+ T cell mediated tumor immunity and drug sensitivity in breast cancer: based on pan-cancer analysis and artificial intelligence modeling of immunogenic cell death-based drug sensitivity stratification.
Li P; Wang W; Wang S; Cao G; Pan T; Huang Y; Wan H; Zhang W; Huang Y; Jin H; Wang Z
Front Immunol; 2023; 14():1145481. PubMed ID: 37388747
[TBL] [Abstract] [Full Text] [Related]
2. Reduction on Proinflammatory Cytokines after Application of Transcutaneous Electrical Nerve Stimulation (TENS) in Patients with a breast cancer: A Nonrandomized, Open, and Single-Arm Study Protocol with Paired Analysis.
do Carmo Almeida TC; Zatta SM; da Silva Paiva L; de Carvalho LEW; Schoueri J; de Abreu LC; Fonseca FLA; Adami F
Mediators Inflamm; 2022; 2022():1350813. PubMed ID: 35241969
[TBL] [Abstract] [Full Text] [Related]
3. Super-enhancer-based identification of a BATF3/il-2R-module reveals vulnerabilities in anaplastic large cell lymphoma.
Liang HC; Costanza M; Prutsch N; Zimmerman MW; Gurnhofer E; Montes-Mojarro IA; Abraham BJ; Prokoph N; Stoiber S; Tangermann S; Lobello C; Oppelt J; Anagnostopoulos I; Hielscher T; Pervez S; Klapper W; Zammarchi F; Silva DA; Garcia KC; Baker D; Janz M; Schleussner N; Fend F; Pospíšilová Š; Janiková A; Wallwitz J; Stoiber D; Simonitsch-Klupp I; Cerroni L; Pileri S; de Leval L; Sibon D; Fataccioli V; Gaulard P; Assaf C; Knörr F; Damm-Welk C; Woessmann W; Turner SD; Look AT; Mathas S; Kenner L; Merkel O
Nat Commun; 2021 Sep; 12(1):5577. PubMed ID: 34552066
[TBL] [Abstract] [Full Text] [Related]
4. PD-L1 silencing inhibits triple-negative breast cancer development and upregulates T-cell-induced pro-inflammatory cytokines.
Lotfinejad P; Kazemi T; Safaei S; Amini M; Roshani Asl E; Baghbani E; Sandoghchian Shotorbani S; Jadidi Niaragh F; Derakhshani A; Abdoli Shadbad M; Silvestris N; Baradaran B
Biomed Pharmacother; 2021 Jun; 138():111436. PubMed ID: 33667790
[TBL] [Abstract] [Full Text] [Related]
5. Dynamic biomarkers indicate the immunological benefits provided by Ganoderma spore powder in post-operative breast and lung cancer patients.
Deng Y; Ma J; Tang D; Zhang Q
Clin Transl Oncol; 2021 Jul; 23(7):1481-1490. PubMed ID: 33405051
[TBL] [Abstract] [Full Text] [Related]
6. Contribution of Immune Cells to Glucocorticoid Receptor Expression in breast cancer.
Gandhi S; Elkhanany A; Oshi M; Dai T; Opyrchal M; Mohammadpour H; Repasky EA; Takabe K
Int J Mol Sci; 2020 Jun; 21(13):. PubMed ID: 32629782
[TBL] [Abstract] [Full Text] [Related]
7. Fibroblasts as a Biological Marker for Curative Resection in Pancreatic Ductal Adenocarcinoma.
Katsuta E; Rashid OM; Takabe K
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32485981
[TBL] [Abstract] [Full Text] [Related]
8. Inequality in breast cancer care in a Brazilian capital city: a comparative analysis of narratives.
Cabral ALLV; Giatti L; Martínez-Hernáez Á; Cherchiglia ML
Int J Equity Health; 2019 Jun; 18(1):88. PubMed ID: 31196095
[TBL] [Abstract] [Full Text] [Related]
9. The significance of cytokine-producing B cells in breast tumor-draining lymph nodes.
Mehdipour F; Razmkhah M; Faghih Z; Bagheri M; Talei AR; Ghaderi A
Cell Oncol (Dordr); 2019 Jun; 42(3):381-395. PubMed ID: 30850950
[TBL] [Abstract] [Full Text] [Related]
10. Complete Clinical Remission of Stage IV Triple-Negative breast cancer Lung Metastasis Administering Low-Dose Immune Checkpoint Blockade in Combination With Hyperthermia and Interleukin-2.
Kleef R; Moss R; Szasz AM; Bohdjalian A; Bojar H; Bakacs T
Integr Cancer Ther; 2018 Dec; 17(4):1297-1303. PubMed ID: 30193538
[TBL] [Abstract] [Full Text] [Related]
11. Analysis of pro- and anti-inflammatory cytokine gene variants and serum cytokine levels as prognostic markers in breast cancer.
Kaur RP; Vasudeva K; Singla H; Benipal RPS; Khetarpal P; Munshi A
J Cell Physiol; 2018 Dec; 233(12):9716-9723. PubMed ID: 30078181
[TBL] [Abstract] [Full Text] [Related]
12. Adjuvant Ovarian Suppression, High-dose Chemotherapy and Immunotherapy for Premenopausal Patients with High-risk breast cancer.
Recchia F; Candeloro G; Rosselli M; Bratta M; Pasta V; D'Orazi V; Fumagalli LA; Rea S
Anticancer Res; 2015 Dec; 35(12):6847-53. PubMed ID: 26637906
[TBL] [Abstract] [Full Text] [Related]
13. Elevated C1orf63 expression is correlated with CDK10 and predicts better outcome for advanced breast cancers: a retrospective study.
Hong CQ; Zhang F; You YJ; Qiu WL; Giuliano AE; Cui XJ; Zhang GJ; Cui YK
BMC Cancer; 2015 Jul; 15():548. PubMed ID: 26209438
[TBL] [Abstract] [Full Text] [Related]
14. IL15RA drives antagonistic mechanisms of cancer development and immune control in lymphocyte-enriched triple-negative breast cancers.
Marra P; Mathew S; Grigoriadis A; Wu Y; Kyle-Cezar F; Watkins J; Rashid M; De Rinaldis E; Hessey S; Gazinska P; Hayday A; Tutt A
Cancer Res; 2014 Sep; 74(17):4908-21. PubMed ID: 24980552
[TBL] [Abstract] [Full Text] [Related]
15. Polymalic acid nanobioconjugate for simultaneous immunostimulation and inhibition of tumor growth in HER2/neu-positive breast cancer.
Ding H; Helguera G; Rodríguez JA; Markman J; Luria-Pérez R; Gangalum P; Portilla-Arias J; Inoue S; Daniels-Wells TR; Black K; Holler E; Penichet ML; Ljubimova JY
J Control Release; 2013 Nov; 171(3):322-9. PubMed ID: 23770212
[TBL] [Abstract] [Full Text] [Related]
16. Interleukin-2 gene polymorphisms and prognosis of breast cancer.
Hu XB; Ouyang LZ; Tang LL
Genet Test Mol Biomarkers; 2013 Jun; 17(6):453-7. PubMed ID: 23477313
[TBL] [Abstract] [Full Text] [Related]
17. Effect of high-dose intravenous vitamin C on inflammation in cancer patients.
Mikirova N; Casciari J; Rogers A; Taylor P
J Transl Med; 2012 Sep; 10():189. PubMed ID: 22963460
[TBL] [Abstract] [Full Text] [Related]
18. Stem and progenitor cell-mediated tumor selective gene therapy.
Aboody KS; Najbauer J; Danks MK
Gene Ther; 2008 May; 15(10):739-52. PubMed ID: 18369324
[TBL] [Abstract] [Full Text] [Related]
19. Trastuzumab activates allogeneic or autologous antibody-dependent cellular cytotoxicity against malignant rhabdoid tumor cells and interleukin-2 augments the cytotoxicity.
Katsumi Y; Kuwahara Y; Tamura S; Kikuchi K; Otabe O; Tsuchiya K; Iehara T; Kuroda H; Hosoi H; Sugimoto T
Clin Cancer Res; 2008 Feb; 14(4):1192-9. PubMed ID: 18281554
[TBL] [Abstract] [Full Text] [Related]
20. Tumor cell expression of HLA-DM associates with a Th1 profile and predicts improved survival in breast carcinoma patients.
Oldford SA; Robb JD; Codner D; Gadag V; Watson PH; Drover S
Int Immunol; 2006 Nov; 18(11):1591-602. PubMed ID: 16987935
[TBL] [Abstract] [Full Text] [Related]
[Next]
